



INNOVATION | QUALITY | CARE

Date: April 24, 2026

To,
The Manager
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street – Fort
Mumbai 400 001
Scrip Code: 544578

To,
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th floor, Plot no. C/1, G Block
Bandra Kurla Complex, Bandra (East),
Mumbai - 400 051
NSE Symbol: RUBICON

Subject: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Outcome of USFDA inspection at the Company’s R&D facility in Canada

Dear Sir / Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please be informed that the United States Food and Drug Administration (USFDA) conducted an unannounced inspection at the Company’s R&D facility located at Concord, Ontario, Canada, from April 20, 2026 to April 24, 2026.

The inspection concluded without any Form-483 being issued.

We remain committed to maintaining the highest standards of compliance and quality.

This is for your information and record.

Yours faithfully,

For Rubicon Research Limited

(Formerly known as Rubicon Research Private Limited)

Deepashree Tanksale
Company Secretary
M. No. A28132

Rubicon Research Limited (formerly known as Rubicon Research Private Limited) | CIN: L73100MH1999PLC119744

Registered Office: Plot No. B-75, MedOne House, Road No. 33, Wagle Estate, Thane West, PIN – 400 604, Maharashtra, India

+91-22-61414000 / 50414000 | reachus@rubicon.co.in | www.rubicon.co.in